Back to all articles
•Technology

10x Science: Revolutionizing Drug Development with AI-Powered Platform

View original source

10x Science, a startup founded in December 2025, has announced a $4.8 million seed funding round led by Initialized Capital, backed by Y Combinator, Civilization Ventures, and Founder Factor. The company aims to address bottlenecks in biopharma drug candidate characterization using a novel AI-powered platform.

  • Founders: Chemical biologist David Roberts, biologist Andrew Reiter, and computer science expert Vishnu Tejus, all with ties to Stanford's Dr. Carolyn Bertozzi.
  • Challenge: The rapid progression of AI in drug discovery is outpacing the ability to characterize molecular candidates effectively.
  • Technology: By integrating deterministic algorithms with AI, the platform allows accurate interpretation of complex mass spectrometry data, essential for regulatory compliance and drug development.
  • Impact: Matthew Crawford of Rilas Technologies supports the platform's ability to explain conclusions, streamline data analyses, and adapt to diverse molecules, providing a valuable asset for biotech companies and academia.
  • Market Application: The platform's SaaS model offers consistent revenue from pharmaceutical firms, with potential expansion into broader molecular intelligence insights.
  • Future: With funding, 10x Science plans to enhance its platform and expand its team, aiming to transform the biotech landscape with AI-driven solutions.